Tap into the overseas PD-1/L1 monoclonal antibody market Livzon Group "follows the trend" and enters the game

Recently, Livzonumab, a subsidiary of Livzon Group, has reached a research cooperation and licensing agreement with Bright Peak Therapeutics (hereinafter referred to as BPTx) in the United States

According to the agreement, Livzumab will license the recombinant humanized anti-PD-1 monoclonal antibody for injection (LZM009) with independent intellectual property rights (LZM009) to BPTx for a paid and non-exclusive license for the development of new PD-1 targeted immune cytokines (PD- 1 ICs), while authorizing LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China

LZM009 is a human IgG4 monoclonal antibody that binds to PD-1 molecules on the surface of T cells to block the PD-1/PD-1 pathway and reactivate T cells to kill cancer cells

At present, 8 PD-1 monoclonal antibodies and 2 PD-L1 monoclonal antibodies have been approved in China, and many PD-1/L1 monoclonal antibodies have been submitted for marketing applications.

For this reason, companies are also targeting overseas markets

➢In March 2015, Cinda Biotech and Eli Lilly reached a strategic cooperation agreement to authorize the overseas market of Sintilimab to Eli Lilly

➢In September 2015, Hengrui signed a cooperative development agreement with Incyte, granting SHR-1210 (ie Carrelizumab) the exclusive global clinical development and market sales rights except for Mainland China, Hong Kong, Macau and Taiwan.

➢ In July 2017, BeiGene and Xinji reached a global cooperation in the field of immuno-oncology, and authorized the global rights of BGB-A317 (ie tislelizumab) in Asia (except Japan) to Xinji

➢ In August 2017, Yuheng Biotech and WuXi Biologics exclusively authorized the international rights of zimberelimab (ie, sepalimumab) to Arcus Biosciences, with a total contract value of US$816 million

➢In August 2018, Kelun Pharmaceutical Holdings subsidiary Kelun Botai licensed its anti-PD-L1 monoclonal antibody project with independent intellectual property rights to Harbour Company for exclusive and paid license for exclusion from China (including Hong Kong, China, Macau, China, and China).

➢ In December 2019, Corning Jereh, TRACON Pharmaceuticals and Sidi Di reached a strategic cooperation, Tracon obtained KN035 (ie Envolimab) in the United States, Canada, Mexico and their respective territories (cooperative regions) in the field of human sarcoma treatment methods Exclusive and non-transferable license on

➢ In April 2020, Hengrui Medicine authorized the exclusive clinical development, registration and marketing rights of Carrelizumab in Korea to Crystal Genomics with a total transaction amount of US$87.

➢ In October 2020, CStone Pharmaceuticals and EQRx reached a strategic cooperation to develop sugarizumab (CS1001, anti-PD-L1 monoclonal antibody) and CS1003 (anti-PD-1 monoclonal antibody) outside of Greater China And the commercialization rights are exclusively authorized EQRx

➢In January 2021, BeiGene and Novartis reached a cooperation and licensing agreement.

➢In February 2021, Junshi Biosciences and Coherus BioSciences reached a cooperation on the development and commercialization of Tereprizumab in the United States and Canada